(News Bulletin 247) – Invest Securities maintains its buy rating on Valbiotis shares, with an unchanged price target of 12.3 euros.
The analyst believes that the roadmap, shared on Wednesday, is broadly in line with his expectations.
Invest Secruties reports that the publication of the full efficacy report of the REVERSE-IT study is scheduled for September, which should highlight the potential of the product.
Furthermore, the INSIGHT clinical program on TOTUM-854 is slightly behind schedule in terms of recruitment but without impact on the price target.
Finally, partnership discussions on TOTUM-070 continue positively and the structuring of the group continues ahead of the marketing of TOTUM-63 and TOTUM-070 in the 1st half of 24.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
